Search
Menu
All issues Volume 3 / No 1 (December 2015) EPJ Nonlinear Biomed Phys, 3 1 (2015) 6 References
Open Access
Issue
EPJ Nonlinear Biomed Phys
Volume 3, Number 1, December 2015
Article Number 6
Number of page(s) 18
DOI https://doi.org/10.1140/epjnbp/s40366-015-0023-3
Published online 11 August 2015
  1. Onitilo AA, Engel JM, Greenlee RT, Mukesh BN. Breast cancer subtypes based on ER/PR and Her2 expression. Comparison of clinicopathologic features and survival. Clin Med Res. 2009;7:4–13. [Google Scholar]
  2. Hudis CA, Gianni L. Triple-negative breast cancer: an unmet medical need. Oncologist. 2011;16:1–11. [Google Scholar]
  3. Neves RM, Chin K, Fridlyand J, Yeh J, Baehner FL, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 2006;10:515–27. [Google Scholar]
  4. Heiser LM, Sadanandam A, Kuo W-L, Benz SC, Goldstein TC, et al. Subtype and pathway specific responses to anticancer compounds in breast cancer. Proc Natl Sci Acad USA. 2012;109:2724–9. [Google Scholar]
  5. Shannon CE. A mathematical theory of communication. Bell Syst Tech J. 1948;27(3):379–423. doi:10.1002/j.1538-7305.1948.tb01338.x. [Google Scholar]
  6. Breitkreutz D, Hlatky L, Rietman EA, Tuszynski JA. Molecular signaling network complexity is correlated with cancer patient survivability. Proc Natl Acad Sci U S A. 2012;109:9209–12. [Google Scholar]
  7. Carels N, Tilli T, Tuszynski JA. A computational strategy to select optimized protein targets for drug development toward the control of cancer diseases. PLoS One. 2015;10:e0115054. [Google Scholar]
  8. Breitkreutz D, Rietman EA, Hinow P, Healey L, Tuszynski JA. Complexity of molecular signaling networks for various types of cancer and neurological diseases correlates with patient survivability. In: BIOMAT 2013. Singapore: World Scientific; 2014. p. 250–62. [Google Scholar]
  9. Shepelev V, Fedorov A. Advances in the exon-intron database. Brief Bioinform. 2006;7:178–85. [Google Scholar]
  10. Mortazavi A, Williams BA, McCue K, Schaeffer L, Wold B. Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat Methods. 2008;5:621–8. [Google Scholar]
  11. Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics. 2003;19:185–93. [Google Scholar]
  12. Cheang MCU, Voduc D, Bajdik C, Leung S, McKinney S, et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res. 2008;14:1368–76. [Google Scholar]
  13. Carels N, Frias D. A statistical method without training step for the classification of coding frame in transcriptome sequences. Bioinformatics Biol Insights. 2013;7:35–54. [Google Scholar]
  14. Kim M-S, Pinto SM, Getnet D, Nirujogi RS, Manda SS, et al. A draft map of the human proteome. Nature. 2014. doi:10.1038/nature13302. [Google Scholar]
  15. Arteaga CL, Engelman JA. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell. 2014;25:282–303. [Google Scholar]
  16. Bury M, Andolfi A, Rogister B, Cimmino A, Mégalizzi V, et al. Fusicoccin a, a phytotoxic carbotricyclic diterpene glucoside of fungal origin, reduces proliferation and invasion of glioblastoma cells by targeting multiple tyrosine kinases. Transl Oncol. 2013;6:112–23. [Google Scholar]
  17. Cao W, Yang X, Zhou J, Teng Z, Cao L, et al. Targeting 14-3-3 protein, difopein induces apoptosis of human glioma cells and suppresses tumor growth in mice. Apoptosis. 2010;15:230–41. [Google Scholar]
  18. Dong S, Kang S, Lonial S, Khoury HJ, Viallet J, Chen J. Targeting 14-3-3 sensitizes native and mutant BCR-ABL to inhibition with U0126, rapamycin and Bcl-2 inhibitor GX15-070. Leukemia. 2008;22:572–7. [Google Scholar]
  19. Gay B, Suarez S, Caravatti G, Furet P, Meyer T, Schoepfer J. Selective GRB2 SH2 inhibitors as anti-Ras therapy. Int J Cancer. 1999;83:235–41. [Google Scholar]
  20. Giubellino A, Gao Y, Lee S, Lee MJ, Vasselli JR, et al. Inhibition of tumor metastasis by a growth factor receptor bound protein 2 Src homology 2 domain-binding antagonist. Cancer Res. 2007;67:6012–6. [Google Scholar]
  21. Qi W, Shakalya K, Stejskal A, Goldman A, Beeck S, et al. NSC348884, a nucleophosmin inhibitor disrupts oligomer formation and induces apoptosis in human cancer cells. Oncogene. 2008;27:4210–20. [Google Scholar]
  22. Ren H, Chu Z, Mao L. Antibodies targeting hepatoma-derived growth factor as a novel strategy in treating lung cancer. Mol Cancer Ther. 2009;8:1106–12. [Google Scholar]
  23. Schneble EJ, Berry JS, Trappey FA, Clifton GT, Ponniah S, et al. The HER2 peptide nelipepimut-S (E75) vaccine (NeuVax™) in breast cancer patients at risk for recurrence: correlation of immunologic data with clinical response. Immunotherapy. 2014;6:519–31. [Google Scholar]
  24. Flor HH. Current status of the gene-for-gene concept. Annu Rev Phytopathol. 1971;9:275–96. [Google Scholar]
  25. Patocchi A, Walser M, Tartarini S, Broggini GAL, Gennari F, Sansavini S, et al. Identification by genome scanning approach (GSA) of a microsatellite tightly associated with the apple scab resistance gene Vm. Genome. 2005;48:630–6. [Google Scholar]